What Happened
London-based precision fermentation company Better Dairy says it has concluded a self-affirmed GRAS determination in the US for lactopontin, its yeast-produced recombinant protein built on the human osteopontin sequence. According to the company, an independent expert panel reviewed a dossier on composition, manufacturing process, purity and specifications and unanimously judged the ingredient safe under its intended conditions of use. Self-affirmed GRAS does not involve FDA review and is not an FDA approval. The determination covers adult nutrition; the company names healthy aging, gut, joint, skin, immunity and sports recovery as target categories, and says customer launches are planned for the coming months. A US early-life nutrition pathway and filings in Europe and Asia remain in progress.
Why It Matters
Some precision fermentation startups are shifting from bulk dairy proteins toward low-dose, higher-value bioactives. Better Dairy itself moved from animal-free casein to osteopontin, a pivot FoodNavigator linked to higher value and small required quantities. Regulatory status, not titre alone, now gates market entry.
For low-dose bioactives, the real test is less about tank volume and more about specification, consistency and documented safety.
FET's Takeaway
Our analysis: native milk osteopontin carries post-translational modifications, so whether a yeast-made human-sequence version matches them is an open question the sources do not address. Formulators stacking it with lactoferrin or collagen will need stability and interaction testing across heat, pH and shelf life. Low dosing eases fermentation volume, but purity, batch consistency and cost per gram become decisive. Health claims require separate substantiation.
Verification source: vegconomist ↗